Kymera Therapeutics, Inc. Quarterly Cost of Revenue in USD from Q1 2024 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Kymera Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from Q1 2024 to Q2 2025.
  • Kymera Therapeutics, Inc. Cost of Revenue for the quarter ending June 30, 2025 was $11.5M, a 55.3% decline year-over-year.
  • Kymera Therapeutics, Inc. annual Cost of Revenue for 2024 was $47.1M, a 40.1% decline from 2023.
  • Kymera Therapeutics, Inc. annual Cost of Revenue for 2023 was $78.6M, a 67.8% increase from 2022.
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $11.5M -$14.2M -55.3% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $22.1M +$11.8M +115% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q2 2024 $25.7M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $10.3M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.